|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RBPMS2 |
Gene summary for RBPMS2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RBPMS2 | Gene ID | 348093 |
| Gene name | RNA binding protein, mRNA processing factor 2 | |
| Gene Alias | RBPMS2 | |
| Cytomap | 15q22.31 | |
| Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q6ZRY4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 348093 | RBPMS2 | HCC1_Meng | Human | Liver | HCC | 9.89e-32 | 1.21e-01 | 0.0246 |
| 348093 | RBPMS2 | HCC2 | Human | Liver | HCC | 3.33e-09 | 1.94e+00 | 0.5341 |
| 348093 | RBPMS2 | S027 | Human | Liver | HCC | 2.33e-06 | 4.43e-01 | 0.2446 |
| 348093 | RBPMS2 | S028 | Human | Liver | HCC | 2.54e-23 | 8.16e-01 | 0.2503 |
| 348093 | RBPMS2 | S029 | Human | Liver | HCC | 1.18e-26 | 1.01e+00 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Cervix | N_HPV |  |
| Endometrium | AEH |  |
| Endometrium | EEC |  |
| Prostate | BPH |  |
| Prostate | Tumor |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RBPMS2 | SNV | Missense_Mutation | rs774369247 | c.286N>A | p.Glu96Lys | p.E96K | Q6ZRY4 | protein_coding | deleterious(0.01) | possibly_damaging(0.669) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RBPMS2 | SNV | Missense_Mutation | rs752694645 | c.275N>A | p.Arg92His | p.R92H | Q6ZRY4 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| RBPMS2 | SNV | Missense_Mutation | rs752694645 | c.275G>A | p.Arg92His | p.R92H | Q6ZRY4 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RBPMS2 | SNV | Missense_Mutation | c.274N>T | p.Arg92Cys | p.R92C | Q6ZRY4 | protein_coding | deleterious(0.02) | probably_damaging(0.985) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| RBPMS2 | SNV | Missense_Mutation | rs752694645 | c.275N>A | p.Arg92His | p.R92H | Q6ZRY4 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-A5-A0GG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RBPMS2 | SNV | Missense_Mutation | c.274C>T | p.Arg92Cys | p.R92C | Q6ZRY4 | protein_coding | deleterious(0.02) | probably_damaging(0.985) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RBPMS2 | SNV | Missense_Mutation | novel | c.244G>A | p.Glu82Lys | p.E82K | Q6ZRY4 | protein_coding | deleterious(0) | benign(0.349) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RBPMS2 | SNV | Missense_Mutation | rs142321272 | c.409N>T | p.Arg137Trp | p.R137W | Q6ZRY4 | protein_coding | deleterious(0.03) | probably_damaging(0.962) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| RBPMS2 | SNV | Missense_Mutation | rs752694645 | c.275N>A | p.Arg92His | p.R92H | Q6ZRY4 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RBPMS2 | SNV | Missense_Mutation | rs188576967 | c.406G>A | p.Ala136Thr | p.A136T | Q6ZRY4 | protein_coding | tolerated(0.2) | benign(0.01) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |